Mélanie Thill-Tayara

• A global leading IT group before the Paris Court of Appeal to challenge the highest ever fine imposed by the French Competition Authority, and succeeded in securing a partial annulment and significant decrease of the fine by 66%, from €1.1 billion to €371.6 million.
• A global pharmaceutical group before the Paris Court of Appeal following the French Competition Authority’s decision in its landmark investigation relating to an alleged abuse of collective dominance regarding the off-label use of a cancer drug to treat an ophthalmic condition. Dechert managed to have the decision of the French Competition Authority completely overturned  on appeal, securing the annulment of the €444 million fine in its entirety.
• A global animal health company in a complaint before the European Commission leading to the investigation of a potential “killer acquisition”.
• An international manufacturer in cartel investigations both before the European Commission and the French Competition Authority, involving in particular non-price cartel allegations in a context of regulatory changes.
• A major group in the transportation sector before the French courts in the context of both (i) public enforcement proceedings following a decision of the French Competition Authority in the commodity chemicals cartel, and (ii) private enforcement claims for damages.
• Two chains of French and Belgian supermarkets in a follow-on damages claim against three of the cartelists that were found liable by the French Competition Authority for having participated in a cartel in the market for fresh dairy products sold under private label.
• A global biopharmaceutical group in investigations led by the European Commission and the Swiss Competition Commission for potential involvement of a subsidiary in a worldwide cartel.
• A major pharmaceutical firm on the lifecycle management of several drugs in one of their franchises, in the context of biosimilars’ entry on the market, with a focus on product hopping and commercial policies issues.
• A German operator in the context of a cartel procedure before the French Competition Authority and the Paris Court of Appeals for the practices carried out by a former subsidiary.
• A global healthcare leader in first instance and appeal, in a dispute against a biotech startup, relating to the termination of negotiations to invest in the development of new cancer-fighting molecules.
• A leading actor in the field of retirement houses and other specialized care centers, on merger control issues related to the projected acquisition of a controlling stake in Belgium groups.
• A financial services operator in the European Commission's investigation on alleged conducts by seven European banks involving the manipulation of Euribor, the benchmark used, among other things, when pricing bank lending in euros and euro interest rate derivatives.
• FMCG companies in various matters such as: the launching of a new product subject to strict regulations, the analysis of the risk of dominant position on primary and secondary markets related to an innovative range of products; the organization of internal training programs relating to competition, distribution and regulatory rules; the implementation of a joint venture with a competitor; the subscription to a European buying group.
• A major international medical devices company during a dawn-raid conducted by the French Competition Authority relating to an alleged anticompetitive agreement and the subsequent procedural challenges; she succeeded in having the case dismissed by the French competition authority.
• A major international medical devices company on the antitrust and public procurement aspects of a “dual branch” business model implemented across Europe for the supply of medical devices to public hospitals.
• A French supplier of luxury products in the design and implementation of its national and international selective distribution networks, as well as other diverse matters: management of parallel imports matters, negotiation and drafting of licensing agreements for the manufacturing of eyewear, and the negotiation of leases for high-end location boutiques.
• A U.S.-based biopharmaceutical company in an ongoing investigation led by the European Commission with respect to anti-generic strategies, and particularly patent settlements.
• Leading international and national pharmaceutical companies in designing the re-organization of their European and national distribution networks in order to decrease the number of their suppliers and increase efficiencies whilst complying with sectorial regulations and obligations of public service.
• A multinational biotechnology company both on competition and regulatory aspects of an investigation relating to alleged collective dominance and concerted practices of two pharmaceutical companies for having differentiated the therapeutic indications of their products.
• A life sciences company in the interaction with the French professional medical devices association and the French authorities in charge of pricing and reimbursement.
• A U.S.-based laboratory in relation to an in-depth audit of regulatory compliance (French and U.S.) with regard to clinical trials, grants, congresses, interactions with healthcare professionals and government officers; the audit included interviews with reps and the creation of a detailed database of professional expenses with specialized forensic auditors; assisting the client in the review of internal policies in this field.
• An international information technology company providing hardware and software services to consumers, businesses and public customers in cases relating to comparative advertising and abuse of an economic dependency.
• Major companies with respect to their merger filings before the European Commission, the French competition authority and the Moroccan competition authorities.
• A leading research-focused healthcare on the implementation of an internal compliance programme, including the organisation of a mock dawn-raid.
• A Swiss based diagnostic medical device company concerning the possibility to oppose to parallel trade of one of its major products, due to safety reasons.

Includes matters handled at Dechert or prior to joining the firm.

• EU Pharmaceutical Law Forum 2024 — Informa, Brussels, Belgium (May 21-23, 2024)
• Festina [minus] lente: Interim Measure in Digital Markets workshop — 2024 Annual European Competition Lawyers Association Conference, Mallorca, Spain (May 4, 2023)
  
• Presentation and analysis of the Paris Court of Appeal Decision on the Roche/Novartis case — LEEM, Paris, France December 12, 2023)
• 11^th Global Merger Control Conference — Paris, France (December 8, 2023)
• Investigations in the life sciences sector — Cercle Montesquieu Workshop, Paris, France (September 26, 2023)
• Managing competition authorities’ dawnraids — Cercle Montesquieu Workshop, Paris, France (June 30, 2023)
• EU Pharmaceutical Law Forum 2023 — Informa, Brussels, Belgium (May 23-25, 2023)
• Inside Antitrust 2023: Navigating an evolving landscape — Philadelphia, US (March 28, 2023)
• Antitrust: Outsourcing competition law enforcement — GCR Live: Law Leaders Global — Miami, Florida (February 2-3, 2023)
  
• Fundamental matters and open issues: an international perspective panel – Cocurrenze.eu Economic dependence and competition Conference, Firenze, Italy (January 24, 2023)
• 10^th Global Merger Control Conference — Paris, France (December 2, 2022)
• Antitrust and the Scientific Debate — IBA Life Sciences Conference, Paris, France (June 3, 2022)
• EU Pharmaceutical Law Forum 2022 - Informa — Brussels, Belgium (May 17, 2022)
• The Vertical Block Exemption Regulation: Renewal or Revolution? — VBER Conference, Paris, France (May 11, 2022)
• Managing investigations in the Life Sciences sector — Life Sciences Academy, Paris, France (February 15, 2022)
• EU Pharmaceutical Law Forum —Virtual conference (May 17- 20, 2021)
• Private Enforcement Conference — Virtual Conference (April 1, 2021)
• 8th Global Merger Control Conference — Virtual Conference (December 2-4, 2020)
• EU Pharmaceutical Law Forum — Virtual conference (November 16-20, 2020)
• “Navigating Recent Developments in Global Merger Enforcement” — Washington D. C., Paris, Brussels Webinar (October 6, 2020)
• 5th Private Enforcement Conference — Webinar (June 19, 2020)
• Mergers: Filing, review… Is it a 100 % deadlock situation? — Paris, France (April 9, 2020)
• 7th Global Merger Control Conference — Paris, France (December 6, 2019)
• First edition of the mentoring program W@CompetitionFR — Paris, France (July 4, 2019)
• Verticals & Private Enforcement — Advanced EU Competition Law Conference, Brussels, Belgium (November 26, 2019)
• Vertical Restraints and Distribution Conference — Brussels, Belgium (June 26, 2019)
• New Frontiers of Antitrust Conference — Paris, France (June 14, 2019)
• EU Pharmaceutical Law Forum — Informa, Brussels, Belgium (May 21-23, 2019)
• 28th Annual Advanced EU Competition Law Conference — London, UK (May 15, 2019)
• Life Sciences Academy — Paris, France (October 2, 2018)
• Digital challenges for luxury and fashion brands — European Fashion and Luxury Law Conference, Milan, Italy (June 20-21, 2018)
• Interim measures & EU competition proceedings: Is there a case for reform? — Brussels (June 8, 2018)
• EU Pharmaceutical Law Forum — Brussels (May 15, 2018)
• Les transactions en droit de la concurrence : réelle opportunité ou fausse aubaine pour les entreprises? — Paris (May 14, 2018)
• Exploring the politics of competition regulation: How political is competition law? - New Frontiers of Antitrust Conference, Paris (June 26, 2017)
• Rencontre exceptionnelle avec Madame la présidente de l'Autorité de la concurrence — Paris (June 13, 2017)
• EU Pharmaceutical Law Forum — Brussels (May 15, 2017)
• Debating Class Action Mechanisms in the U.S. and EU — ABA Section of Antitrust Law Spring Meeting 2017, Washington, D.C. (March 29, 2017)
• Panorama de jurisprudence : décisions marquantes en droit de la concurrence dans le domaine pharmaceutique en 2016 — 14èmes journées Droit de la Santé et du Médicament, Paris (January 27, 2017)
• M&A et gun-jumping : Etat des lieux et recommandations après la décision Altice du 8 novembre 2016 - Paris, France (January 23, 2016)
• Markets, Remedies and Survival: Cutting Edge Issues in Global Merger Control— 4th Annual Global Merger Control Conference, Paris, France (December 2, 2016)
• Développements récents en droit de la concurrence appliqués au secteur pharmaceutique : Lundbeck, Roche/Novartis, Genentech/Sanofi - Paris (November 15, 2016)
• Remèdes et engagements : une solution de facilité trop engageante? — Business & Legal Forum, Paris, France (October 11, 2016)
• Les défis du droit de la concurrence face au commerce électronique — Colloque APDC — EFB, Paris, France (September 29, 2016)
• Inspections de concurrence : Comment protéger l'entreprise? —  Paris, France (May 31, 2016)
• 25th Annual EU Pharmaceutical Law Forum 2016 — Informa, Brussels, Belgium (May 24, 2016)

• Droit de la concurrence la protection de la relation entreprise-avocat en danger — Les Echos (October 25, 2024)
  
• Pharma & Dominance: An overview of EU and national case law — Revue Concurrences (September 20, 2024)
• Le secteur pharmaceutique, au coeur des priorités des autorités de concurrence en Europe — Blog de l’Usine Nouvelle (May 3, 2024)
• Pharmaceutical Antitrust Book — Concurrences (November 30, 2023)
• Accords de report d'entrée : la sanction de 60,5 millions d'euros pour Teva et Cephalon confirmée — Blog de l’Usine Nouvelle (November 1, 2023)
• Juristes d'entreprises : la confidentialité doit être totale — Les Echos (October 4, 2023)
• The Instrumentalization of Intellectual Property Rights for Anticompetitive Purposes in the Pharmaceutical Industry A New Territory for Competition Authorities in Europe — Concurrences (September 4, 2023)
• France: Pedagogical approach of courts and increased FCA enforcement contribute to rise in private antitrust litigation — Global Competition Review (July 30, 2023)
• Impactful decisions exemplify FCA and Supreme Administrative Court's evolving merger control — Global Competition Review (June 30, 2023)
• Vers un élargissement du champ du contrôle des autorités de concurrence européennes dans les concentrations d’entreprises — Blog de l’Usine Nouvelle (April 14, 2023)
• Dominance in the pharmaceutical sector: An Overview of EU and national case law — Concurrences (February 2, 2023)
• Pourquoi la Commission européenne a interdit l'opération Illumina/Grail — Blog de l’Usine Nouvelle (October 21, 2022)
• Enquête sectorielle par l’ADLC sur le fonctionnement concurrentiel du secteur du cloud — LJA (September 13, 2022)
• Saisie des correspondances avocat-client : la Chambre criminelle maintient sa position restrictive - mais pour combien de temps ? — Lexbase Avocats (July 8, 2022)
• France: changes and firsts for the FCA — Global Competition Review (June 24, 2022)
• Le secteur de la santé sous la présidence d'Emmanuel Macron : rétrospectives et perspectives — Concurrences (March 31, 2022)
• Affaire Plavix : revirement dans le volet « private enforcement » — Blog L’Usine Nouvelle (March 26, 2022)
  
• Principe d’effectivité, notion d’unité économique et responsabilité civile : de quelques enseignements de l’affaire Sumal — Revue Concurrences (February 24, 2022)
• Global Competition Review Cases and Precedents: Vertical Restraints — Global Competition Review (January 3, 2022)
• Cartel Regulation — Getting The Deal Through (Januray 3, 2022)
• Dominance in the Pharmaceutical Sector: An Overview of EU and National Case Law — e-Competitions Review (December 23, 2021)
• Les concentrations de strat-up n'échappent plus à Bruxelles — L'Usine Nouvelle (November 1,  2021)
• Pharmaceutical Antitrust Guide 2021 - Global Overview and EU Chapter — Getting The Deal Through – Lexology (September 7, 2021)
• Vertical Restraints EU — Global Competition Review (September 1, 2021)
• France: Changes and Firsts for the FCA — Global Competition Review (July 14, 2021)
• France: Private Antitrust Litigation- a Practical Guide — Global Competition Review (July 14, 2021)
• "Pay-for-delay": clap de fin dans l’affaire Lundbeck — L'Usine Nouvelle (May 1, 2021)
• Les Sages adressent un message rassurant à l’Autorité de la concurrence — LJA Hebdo (April 12, 2021)
• Digital Market Act : De nouveaux pouvoirs pour la Commission européenne ? — Le Journal du Management Juridique et Réglementaire (March 1, 2021)
• Sanction de Roche et Novartis pour discours « trompeur » sur l’utilisation d’Avastin dans la DMLA : quand l’Autorité de la concurrence s’érige en censeur des communications entre les laboratoires et les autorités de santé — Blog l'Usine Nouvelle (January 22, 2021)
• Cartel Regulation EU 2021 — Getting The Deal Through – Lexology (January 22, 2021)
• Pharmaceutical Antitrust Guide: Pharmaceutical Antitrust in European Union — Getting the Deal Through- Lexology (September 29, 2020)
• Pharmaceutical Antitrust Guide: Pharmaceutical Antitrust: Global Overview — Getting the Deal Through- Lexology (September 29, 2020)
• Europe, Middle East and Africa Antitrust Review 2021 — Global Competition Review (August 17, 2020)
• Covid-19, coopération entre entreprises et concurrence : quelles règles face à la crise ? — L’Usine Nouvelle (May 12, 2020)
• Indemnisation des préjudices résultant de pratiques anticoncurrentielles : le « pass-on » est-il le maillon faible ? — Revue Lamy Droit des Affaires, Revue Lamy de la concurrence (February 1, 2020)
• Concurrence : Indemnisation des préjudices résultant de pratiques anticoncurrentielles : le « pass-on » est-il le maillon faible ? — Lamy (January 22, 2020)
• Dominance in the Pharmaceutical Sector: An Overview of EU and National Case Law — (November 21, 2019)
• 2019 Annual Antitrust Spring Seminar — (March 26, 2019)
  
• Private Enforcement of Competition Law Conference — (February 26, 2019)
• The Servier Judgment: A Breath of Fresh Air for Pharmaceutical Companies? — (December 21, 2018)
• Life Sciences Academy — (October 2, 2018)
  
• Private Equity Newsletter — (September 20, 2018)
• NEW FRONTIERS OF ANTITRUST - OPENING SPEAKERS DINNER - (June 10, 2018)
  
• France: Merger Control - Global Competition Review — (June 1, 2018)
  
• Q&A Guides to Life Sciences in France — (May 1, 2018)